Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial-Reference-Cited by-同舟云学术

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial

Published:2018-07 Issue:7 Volume:19 Page:871-879
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zhu Hong-Hu,Wu De-Pei,Du Xin,Zhang Xi,Liu Lin,Ma Jun,Shao Zong-Hong,Ren Han-Yun,Hu Jian-Da,Xu Kai-Lin,Wang Jing-Wen,Song Yong-Ping,Fang Mei-Yun,Li Juan,Yan Xiao-Yan,Huang Xiao-Jun

Funder

foundation for innovative research group of the National Natural Science Foundation of China

Beijing Municipal Science & Technology Commission

National Key R&D Program of China

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus;de Thé;Nature,1990

2. Acute promyelocytic leukemia: from highly fatal to highly curable;Wang;Blood,2008